CureVac Raises €27.6 Million
CureVac GmbH, a Germany-based developer of mRNA vaccines, has raised €27.6 million in Series C funding from existing shareholder Hopp BioTech Holding GmbH & Co.
11 May 2010•2 mins read
CureVac GmbH, a Germany-based developer of mRNA vaccines, has raised €27.6 million in Series C funding from existing shareholder Hopp BioTech Holding GmbH & Co.
